Clinical Trials
1
Active:0
Completed:0
Trial Phases
0 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials
phase_1_2
1 (100.0%)An interventional, multicenter, and international phase 1/2, light-dose-escalation study to investigate the safety and feasibility of intraoperative photodynamic therapy (PDT) with Pentalafen® drug and Heliance® Solution device in male and female patients 18 to 75 years of age with grade IV glioblastoma.
Phase 1/2
Recruiting
- Conditions
- High-grade glioma Glioblastoma
- First Posted Date
- 2023-02-21
- Last Posted Date
- 2025-08-12
- Lead Sponsor
- Hemerion Therapeutics
- Target Recruit Count
- 6
- Registration Number
- 2025-520563-41-00
- Locations
- 🇺🇸
UPMC Hillman Cancer center, Pittsburgh, Pennsylvania, United States
🇫🇷CHU De Lille, Hôpital Roger Salengro, Lille, France
News
No news found